30 Apr 2014 17:51
30 April 2014
Further to the announcement of 28th April, that RB was in discussions with Merck, RB now confirms that it is no longer in active discussion regarding an offer for Merck's consumer health business.
For further information, please contact:
Reckitt Benckiser Richard Joyce Director, Investor Relations Andraea Dawson-Shepherd SVP, Global Corporate Communication & Affairs | +44 (0)1753 217800 |
Brunswick (Financial PR) David Litterick
| +44 (0)20 7404 5959
|
Cautionary note concerning forward-looking statements
This document contains statements with respect to the financial condition, results of operations and business of RB and certain of the plans and objectives of the Group with respect to these items. These forward-looking statements are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing to the Company, anticipated cost savings or synergies and the completion of strategic transactions are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors discussed in this report, that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside Reckitt Benckiser's control. Past performance cannot be relied upon as a guide to future performance.